NeuroSense Therapeutics
NRSN
10 hedge funds and large institutions have $347K invested in NeuroSense Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 8 closing their positions.
1.02% less ownership
Funds ownership: 2.13% → 1.11% (-1%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
41% less funds holding
Funds holding: 17 → 10 (-7)
64% less capital invested
Capital invested by funds: $964K → $347K (-$618K)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$66.5K |
| 2 |
Two Sigma Investments
New York
|
+$30.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$19.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$282K |
| 2 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$113K |
| 3 |
Jane Street
New York
|
-$54.2K |
| 4 |
HF
HRT Financial
New York
|
-$41K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$22.4K |
NRSN Hedge Fund Activity: Q3 2025 in Review
10 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2025, worth a combined $347K — down 64% from $964K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NRSN and 1 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Squarepoint, adding an estimated $66.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $282K sold.
- 10 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2025, down from 17 in Q2 2025.
- Funds reported $347K of NeuroSense Therapeutics stock for Q3 2025, down 64% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics positions in Q3 2025 and 8 closed out, a net change of -7 holders.
- The largest NeuroSense Therapeutics buyer in Q3 2025 was Squarepoint, an estimated $66.5K added.
- The largest NeuroSense Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $282K sold.
Based on aggregated 13F filings for Q3 2025.